Financial Results for the Second Quarter of
Fiscal Year Ending March 31, 2024 (FY2023)

from the beginning

Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2024 (FY2023)

• Forward-Looking Statements and Use of Document

• Highlights

• P&L

• OP Variance Analysis (Q2): Less inflation impact, profitability improvement progress

• OP Variance Analysis (Q2 YTD): As planned in all areas

• Gross Margin: Substantial 2H improvement expected

• Revenue by Region: Therapeutic devices strong in Americas, EU; Emerging drove high growth rate

• C&V: Americas, EU drove continuing strong sales; profitprogress as planned

• TMCS: Increased sales and profit despite impact of Nutrition business divestiture, return to normal of thermometers

• TBCT: Strong blood center business drove large profit increase

Reference

• Revenue by Segment and Region

• Quarterly Revenue Trend

• Profitability Improvement Progress

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustment Items

• CAPEX, Depreciation and Amortization,R&D Expenses

• Cash Flows (Q2 YTD)

• Cash Flows (Q2)

• FY23 Q2 YTD FX Impact Breakdown (Flow, Stock)

• Foreign Exchange Sensitivity

@

Solution Pipeline for Beyond GS26

• Forward-Looking Statements and Use of Document

• Top-line growth is the cornerstone of growth strategy

• Solution pipeline built on a stable growth platform

• US-Japan DSS (Dual sensor system) Ushering in a new era of endovascular imaging

• EU Quirem (Radioactive beads) A new option to localized oncology therapies

• Antibody for Alzheimer’s disease (Pen type auto-injector) Expand CDMO pipeline in Japan

• CDMO Overseas Expansion (B2B with overseas pharma firms) Expand CDMO pipeline overseas

• US Reveos (Automated whole blood processing system) Contribute to enhance supply capability of platelet

• US Rika (Source plasma collection system) Innovations for plasma collection centers (faster, more, safer)

• Beyond GS26 - R&D focus areas oriented further into the future

• Portfolio optimization

• Realize sustainable growth by creating value for society

@